Data / Companies / CLOV
Clover Health Investments, Corp.Nasdaq
CLOV-US · CIK 0001801170 · Hospital & Medical Service Plans
Revenue by quarter
US$ · last 8Hover a column for its exact figure
$0$200M$400M$600M$800M
Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
| Quarter | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $743.2M | $28.0M | 0.05 |
| Q1 FY2026 | $749.2M | $27.3M | 0.05 |
| Q4 FY2025 | $487.7M | -$49.3M | -0.10 |
| Q3 FY2025 | $496.6M | -$24.4M | -0.05 |
Newest filings
All 251| Form | Filed | Accepted (ET) | |
|---|---|---|---|
| 8-K | 9 Oct 2026 | 8 Oct, 7:13 PM | |
| 8-K/A | 25 Sep 2026 | ||
| 8-K | 24 Sep 2026 | ||
| 8-K | 20 Aug 2026 | ||
| 10-Q | 7 Aug 2026 | ||
| 8-K | 5 Aug 2026 | ||
| 8-K | 17 Jul 2026 | ||
| 8-K | 18 Jun 2026 |
Description
- Ticker
- CLOV-US
- Exchange
- Nasdaq
- Index
- –
- Industry
- Hospital & Medical Service Plans
- SIC division
- Finance, insurance and real estate
- CIK
- 0001801170
- Fiscal year ends
- Dec
- Filings held
- 251 since 2020
- 8-K events
- 104
- Shares short
- 25.9M, 15 Oct 2026
Financial statements
The main lines of the income statement, balance sheet and cash flow, by year and by quarter. Each period opens its filing.
5 years · US$ millions
| Fiscal period | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Period ending | 31 Dec 2021 | 31 Dec 2022 | 31 Dec 2023 | 31 Dec 2024 | 31 Dec 2025 |
| Reported in | 10-K | 10-K | 10-K | 10-K | 10-K |
| Report filed | 28 Feb 2022 | 3 Mar 2025† | 3 Mar 2025† | 3 Mar 2025 | 27 Feb 2026 |
| Revenue | 1,472M | 1,097M | 1,261M | 1,371M | 1,924M |
| Gross profit | -79M | – | – | – | – |
| Gross margin | -5.4% | – | – | – | – |
| Operating income | -637M | -287M | -205M | -46M | -86M |
| Operating margin | -43.3% | -26.1% | -16.3% | -3.3% | -4.4% |
| Profit before tax | – | – | -213M | -43M | -86M |
| Income tax | 0M | 0M | 0M | 0M | 0M |
| Net income | -588M | -340M | -213M | -43M | -86M |
| Net margin | -39.9% | -31.0% | -16.9% | -3.1% | -4.4% |
| Earnings per share, diluted | -1.42 | -0.71 | -0.44 | – | -0.17 |
| Diluted shares | 413M | 476M | 482M | 490M | 512M |
† FY2022: figures as restated in 10-K filed 3 Mar 2025.
† FY2023: figures as restated in 10-K filed 3 Mar 2025.
Showing the last 5 years, FY2021 onwards. The full record goes back to FY2019 and comes with a data plan. See the data plans
Ratios
Worked out the same way for every company. Hover a ratio for how it is calculated.
Valuation
- Market cap
- $2.5B
- Price
- $4.57
- Price to book
- 6.63×
- Enterprise value
- $2.3B
- Market cap / sales
- 1.01×
- 52-week high
- $5.41
- 52-week low
- $1.70
Profitability
- Operating margin
- -0.7%
- Net margin
- -0.7%
- FCF margin
- 3.0%
- ROE
- -4.9%
- ROE, 3-year average
- -38.3%
- ROCE
- -4.9%
Growth
- Sales growth, TTM
- 54.0%
- Sales CAGR, 3 years
- 20.6%
- Sales CAGR, 5 years
- 23.4%
- Price, 1 year
- 25.5%
- Price CAGR, 3 years
- 71.2%
- Price CAGR, 5 years
- -9.4%
Balance sheet
- Cash and equivalents
- $198.8M
- Borrowings
- $0
- Net debt
- -$198.8M
- Debt to equity
- 0.00×
- Shareholders' equity
- $376.3M
- Total assets
- $720.3M
- Net debt change, 1 year
- -$10.2M
Shareholders
- Share count, last 12 months
- 3.0%
- Buybacks, TTM
- $1.0K
- Years FCF margin > 20%, of 5
- 0
Showing the last 5 years, FY2021 onwards. The full record goes back to FY2019 and comes with a data plan. See the data plans
What the company said with its results
The key points, guidance and management's own words from each of the last four results releases.
No results summary read for this company yet.
Revenue by segment
As the company reports it in the segment note of each annual report: by business, by product and by region, latest year.
This company reports no segment split in its annual report.
Showing the last 5 years, FY2021 onwards. The full record goes back to FY2019 and comes with a data plan. See the data plans
Company events
Every 8-K, sorted by the event it reports, with the moment the SEC accepted it in New York time.
| 9 Oct 2026 | 8 Oct, 7:13 PM ET | 8-K | Investor update | 7.01, 9.01 | |
| 25 Sep 2026 | 8-K/A | Leadership change | 5.02, 9.01 | ||
| 24 Sep 2026 | 8-K | Leadership change | 5.02, 9.01 | ||
| 20 Aug 2026 | 8-K | Investor update | 7.01, 9.01 | ||
| 5 Aug 2026 | 8-K | Results | 2.02, 9.01 | ||
| 17 Jul 2026 | 8-K | Other events | 8.01 | ||
| 18 Jun 2026 | 8-K | Other events | 8.01 | ||
| 16 Jun 2026 | 8-K | Leadership change | 5.02 | ||
| 12 Jun 2026 | 8-K | Shareholder vote | 5.07 | ||
| 10 Jun 2026 | 8-K | Other events | 8.01 | ||
| 18 May 2026 | 8-K | Investor update | 7.01, 9.01 | ||
| 6 May 2026 | 8-K | Results | 2.02, 9.01 | ||
| 1 Apr 2026 | 8-K | Leadership changeOther events | 5.02, 8.01 | ||
| 6 Mar 2026 | 8-K/A | Investor update | 7.01, 9.01 | ||
| 6 Mar 2026 | 8-K | Investor update | 7.01, 9.01 | ||
| 26 Feb 2026 | 8-K | Results | 2.02, 9.01 | ||
| 14 Jan 2026 | 8-K | Investor update | 7.01, 9.01 | ||
| 10 Dec 2025 | 8-K | Investor update | 7.01, 9.01 | ||
| 12 Nov 2025 | 8-K | Investor update | 7.01, 9.01 | ||
| 4 Nov 2025 | 8-K | Investor update | 7.01, 9.01 | ||
| 31 Oct 2025 | 8-K | Leadership change | 5.02, 9.01 | ||
| 9 Oct 2025 | 8-K | Investor update | 7.01, 9.01 | ||
| 11 Aug 2025 | 8-K | Investor update | 7.01, 9.01 | ||
| 5 Aug 2025 | 8-K | Results | 2.02, 9.01 | ||
| 12 Jun 2025 | 8-K | Shareholder vote | 5.07 | ||
| 14 May 2025 | 8-K | Investor update | 7.01, 9.01 | ||
| 6 May 2025 | 8-K | Results | 2.02, 9.01 | ||
| 22 Apr 2025 | 8-K | Leadership change | 5.02, 9.01 | ||
| 27 Feb 2025 | 8-K | Results | 2.02, 9.01 | ||
| 13 Jan 2025 | 8-K | Investor update | 7.01, 9.01 | ||
| 6 Nov 2024 | 8-K | Results | 2.02, 9.01 | ||
| 25 Oct 2024 | 8-K | Other events | 8.01 | ||
| 10 Oct 2024 | 8-K | Investor update | 7.01, 9.01 | ||
| 30 Sep 2024 | 8-K | Other events | 8.01 | ||
| 22 Aug 2024 | 8-K | Leadership change | 5.02, 9.01 | ||
| 5 Aug 2024 | 8-K | Results | 2.02, 9.01 | ||
| 19 Jul 2024 | 8-K | Other events | 8.01, 9.01 | ||
| 26 Jun 2024 | 8-K | Other events | 8.01, 9.01 | ||
| 25 Jun 2024 | 8-K | Bylaws or fiscal year change | 5.03, 9.01 | ||
| 14 Jun 2024 | 8-K | Investor update | 7.01, 9.01 | ||
| 13 Jun 2024 | 8-K | Shareholder vote | 5.07 | ||
| 29 May 2024 | 8-K | Investor update | 7.01, 9.01 | ||
| 7 May 2024 | 8-K | ResultsOther events | 2.02, 8.01, 9.01 | ||
| 22 Apr 2024 | 8-K | Leadership change | 5.02, 9.01 | ||
| 5 Apr 2024 | 8-K | Delisting notice | 3.01 | ||
| 4 Apr 2024 | 8-K | Other events | 8.01, 9.01 | ||
| 12 Mar 2024 | 8-K | Results | 2.02, 9.01 | ||
| 10 Jan 2024 | 8-K | Investor update | 7.01, 9.01 | ||
| 27 Dec 2023 | 8-K | Leadership change | 5.02 | ||
| 21 Dec 2023 | 8-K | Leadership changeOther events | 5.02, 8.01, 9.01 |
1–50 of 104
8-K events each year
Hover a column for its exact count
05101520
'20'24'26
Every filing
The company's filings with the SEC, newest first: 251 held. Insider, fund and large-holder filings have their own tables below.
| 9 Oct 2026 | 8-K | 8 Oct 2026 | 8 Oct, 7:13 PM ET | |
| 25 Sep 2026 | 8-K/A | 22 Sep 2026 | ||
| 24 Sep 2026 | 8-K | 22 Sep 2026 | ||
| 20 Aug 2026 | 8-K | 20 Aug 2026 | ||
| 7 Aug 2026 | 10-Q | 30 Jun 2026 | ||
| 5 Aug 2026 | 8-K | 5 Aug 2026 | ||
| 17 Jul 2026 | 8-K | 4 Jul 2026 | ||
| 18 Jun 2026 | 8-K | 17 Jun 2026 | ||
| 16 Jun 2026 | 8-K | 15 Jun 2026 | ||
| 12 Jun 2026 | 8-K | 10 Jun 2026 | ||
| 10 Jun 2026 | 8-K | 9 Jun 2026 | ||
| 18 May 2026 | 8-K | 18 May 2026 | ||
| 8 May 2026 | 10-Q | 31 Mar 2026 | ||
| 6 May 2026 | 8-K | 6 May 2026 | ||
| 28 Apr 2026 | ARS | 31 Dec 2025 | ||
| 28 Apr 2026 | DEFA14A | – | ||
| 28 Apr 2026 | DEF 14A | 28 Apr 2026 | ||
| 1 Apr 2026 | 8-K | 30 Mar 2026 | ||
| 10 Mar 2026 | S-8 | – | ||
| 6 Mar 2026 | 8-K/A | 6 Mar 2026 | ||
| 6 Mar 2026 | 8-K | 6 Mar 2026 | ||
| 27 Feb 2026 | 10-K | 31 Dec 2025 | ||
| 26 Feb 2026 | 8-K | 26 Feb 2026 | ||
| 14 Jan 2026 | 8-K | 14 Jan 2026 | ||
| 10 Dec 2025 | 8-K | 10 Dec 2025 | ||
| 12 Nov 2025 | 8-K | 12 Nov 2025 | ||
| 7 Nov 2025 | 10-Q | 30 Sep 2025 | ||
| 4 Nov 2025 | 8-K | 4 Nov 2025 | ||
| 31 Oct 2025 | 8-K | 31 Oct 2025 | ||
| 9 Oct 2025 | 8-K | 9 Oct 2025 | ||
| 11 Aug 2025 | 8-K | 11 Aug 2025 | ||
| 8 Aug 2025 | 10-Q | 30 Jun 2025 | ||
| 5 Aug 2025 | 8-K | 5 Aug 2025 | ||
| 12 Jun 2025 | 8-K | 10 Jun 2025 | ||
| 14 May 2025 | 8-K | 14 May 2025 | ||
| 9 May 2025 | 10-Q | 31 Mar 2025 | ||
| 6 May 2025 | 8-K | 6 May 2025 | ||
| 28 Apr 2025 | ARS | 31 Dec 2024 | ||
| 28 Apr 2025 | DEFA14A | – | ||
| 28 Apr 2025 | DEF 14A | 28 Apr 2025 | ||
| 22 Apr 2025 | 8-K | 21 Apr 2025 | ||
| 7 Mar 2025 | S-8 | – | ||
| 3 Mar 2025 | 10-K | 31 Dec 2024 | ||
| 27 Feb 2025 | 8-K | 27 Feb 2025 | ||
| 13 Jan 2025 | 8-K | 13 Jan 2025 | ||
| 8 Nov 2024 | 10-Q | 30 Sep 2024 | ||
| 6 Nov 2024 | 8-K | 6 Nov 2024 | ||
| 25 Oct 2024 | 8-K | 23 Oct 2024 | ||
| 10 Oct 2024 | 8-K | 10 Oct 2024 | ||
| 30 Sep 2024 | 8-K | 26 Sep 2024 |
1–50 of 150
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months, with the shares they held after.
| 20 Oct 2026 | Soares KarenChief Legal Officer | Sale under a trading plan | 19,275 | $4.66 | $89.8K | 1,573,423 | 20 Oct 2026 |
| 19 Oct 2026 | Reynoso Jamie L.CEO, Medicare Advantage | Sale under a trading plan | 4,066 | $4.41 | $17.9K | 2,770,351 | 20 Oct 2026 |
| 15 Oct 2026 | Toy AndrewChief Executive Officer | Sale under a trading plan | 62,176 | $4.68 | $291.0K | 9,078,334 | 19 Oct 2026 |
| 15 Oct 2026 | Soares KarenChief Legal Officer | Sale under a trading plan | 14,673 | $4.68 | $68.7K | 1,592,698 | 19 Oct 2026 |
| 15 Oct 2026 | Thornton Joseph ClayInterim CFO | Sale under a trading plan | 4,591 | $4.68 | $21.5K | 1,244,935 | 19 Oct 2026 |
| 15 Oct 2026 | Wai ConradCEO, Counterpart Health | Sale under a trading plan | 23,627 | $4.68 | $110.6K | 1,042,072 | 19 Oct 2026 |
| 15 Oct 2026 | Reynoso Jamie L.CEO, Medicare Advantage | Sale under a trading plan | 18,273 | $4.68 | $85.5K | 2,774,417 | 19 Oct 2026 |
| 7 Oct 2026 | Reynoso Jamie L.CEO, Medicare Advantage | Sale under a trading plan | 2,006 | $4.63 | $9.3K | 2,792,690 | 7 Oct 2026 |
| 5 Oct 2026 | Reynoso Jamie L.CEO, Medicare Advantage | Sale under a trading plan | 8,750 | $4.42 | $38.7K | 2,794,696 | 5 Oct 2026 |
| 1 Oct 2026 | Toy AndrewChief Executive Officer | Sale under a trading plan | 318,806 | $4.19 | $1.3M | 9,140,510 | 2 Oct 2026 |
| 17 Sep 2026 | Reynoso Jamie L.CEO, Medicare Advantage | Sale under a trading plan | 1,921 | $4.56 | $8.8K | 2,803,446 | 18 Sep 2026 |
| 16 Sep 2026 | Oldakowski Joseph FrankVP OF FINANCE AND CONTROLLER | Sale under a trading plan | 3,170 | $4.64 | $14.7K | 275,897 | 17 Sep 2026 |
| 15 Sep 2026 | Wai ConradCEO, Counterpart Health | Sale under a trading plan | 300,000 | $4.72 | $1.4M | 1,170,056 | 16 Sep 2026 |
| 15 Sep 2026 | Soares KarenChief Legal Officer | Sale under a trading plan | 6,846 | $4.78 | $32.7K | 1,607,371 | 15 Sep 2026 |
| 15 Sep 2026 | Reynoso Jamie L.CEO, Medicare Advantage | Sale under a trading plan | 9,273 | $4.78 | $44.3K | 2,805,367 | 15 Sep 2026 |
| 14 Sep 2026 | Oldakowski Joseph FrankVP OF FINANCE AND CONTROLLER | Sale outside a trading plan | 20,000 | $5.16 | $103.2K | 279,067 | 14 Sep 2026 |
| 17 Aug 2026 | Thornton Joseph ClayInterim CFO | Sale under a trading plan | 17,775 | $4.39 | $78.0K | 1,249,526 | 17 Aug 2026 |
| 10 Aug 2026 | Toy AndrewChief Executive Officer | Sale under a trading plan | 87,798 | $4.65 | $408.3K | 9,459,316 | 10 Aug 2026 |
| 20 Jul 2026 | Soares KarenChief Legal Officer | Sale under a trading plan | 51,700 | $4.51 | $233.2K | 1,505,522 | 20 Jul 2026 |
| 17 Jul 2026 | Reynoso Jamie L.CEO, Medicare Advantage | Sale under a trading plan | 4,839 | $4.53 | $21.9K | 2,814,640 | 17 Jul 2026 |
| 15 Jul 2026 | Toy AndrewChief Executive Officer | Sale under a trading plan | 62,711 | $4.67 | $292.9K | 9,547,114 | 16 Jul 2026 |
| 15 Jul 2026 | Wai ConradCEO, Counterpart Health | Sale under a trading plan | 24,215 | $4.67 | $113.1K | 1,145,699 | 16 Jul 2026 |
| 15 Jul 2026 | Reynoso Jamie L.CEO, Medicare Advantage | Sale under a trading plan | 13,119 | $4.67 | $61.3K | 2,819,479 | 16 Jul 2026 |
| 15 Jul 2026 | Soares KarenChief Legal Officer | Sale under a trading plan | 10,519 | $4.67 | $49.1K | 1,557,222 | 16 Jul 2026 |
| 15 Jul 2026 | Thornton Joseph ClayInterim CFO | Sale under a trading plan | 4,630 | $4.67 | $21.6K | 1,212,954 | 16 Jul 2026 |
| 8 Jul 2026 | Reynoso Jamie L.CEO, Medicare Advantage | Sale under a trading plan | 2,384 | $4.68 | $11.2K | 2,832,598 | 9 Jul 2026 |
| 6 Jul 2026 | Reynoso Jamie L.CEO, Medicare Advantage | Sale under a trading plan | 6,229 | $5.26 | $32.8K | 2,834,982 | 6 Jul 2026 |
| 1 Jul 2026 | Toy AndrewChief Executive Officer | Sale under a trading plan | 313,476 | $5.32 | $1.7M | 9,609,825 | 1 Jul 2026 |
| 17 Jun 2026 | Reynoso Jamie L.CEO, Medicare Advantage | Sale under a trading plan | 2,360 | $4.78 | $11.3K | 2,841,211 | 18 Jun 2026 |
| 16 Jun 2026 | Oldakowski Joseph FrankVP OF FINANCE AND CONTROLLER | Sale under a trading plan | 12,102 | $4.86 | $58.8K | 299,067 | 17 Jun 2026 |
| 15 Jun 2026 | Soares KarenChief Legal Officer | Sale under a trading plan | 4,681 | $4.61 | $21.6K | 1,567,741 | 16 Jun 2026 |
| 15 Jun 2026 | Reynoso Jamie L.CEO, Medicare Advantage | Sale under a trading plan | 6,350 | $4.61 | $29.3K | 2,843,571 | 16 Jun 2026 |
| 11 Jun 2026 | Reynoso Jamie L.CEO, Medicare Advantage | Sale under a trading plan | 7,289 | $4.91 | $35.8K | 2,849,921 | 11 Jun 2026 |
| 28 May 2026 | Wai ConradCEO, Counterpart Health | Sale under a trading plan | 220,426 | $3.99 | $879.5K | 1,390,056 | 28 May 2026 |
| 18 May 2026 | Edwards Carladenise ArmbristerDirector | Sale outside a trading plan | 67,160 | $3.42 | $229.7K | 285,432 | 19 May 2026 |
| 13 May 2026 | Priest Brady PatrickCEO of Clover Care Services | Sale outside a trading plan | 98,039 | $3.52 | $345.1K | 2,040,222 | 13 May 2026 |
| 18 Mar 2026 | Reynoso Jamie L.CEO, Medicare Advantage | Sale under a trading plan | 5,833 | $1.91 | $11.1K | 2,716,735 | 18 Mar 2026 |
| 4 Mar 2026 | Priest Brady PatrickCEO of Home Care | Sale outside a trading plan | 175,000 | $2.17 | $379.8K | 1,998,584 | 5 Mar 2026 |
| 20 Jan 2026 | Reynoso Jamie L.CEO, Medicare Advantage | Sale under a trading plan | 4,597 | $2.58 | $11.9K | 2,737,700 | 20 Jan 2026 |
| 7 Jan 2026 | Reynoso Jamie L.CEO, Medicare Advantage | Sale under a trading plan | 2,102 | $2.53 | $5.3K | 2,757,029 | 7 Jan 2026 |
| 18 Dec 2025 | Reynoso Jamie L.CEO, Medicare Advantage | Sale under a trading plan | 4,913 | $2.61 | $12.8K | 2,767,240 | 18 Dec 2025 |
| 4 Nov 2025 | Reynoso Jamie L.CEO, Medicare Advantage | Sale under a trading plan | 30,385 | $3.58 | $108.8K | 2,793,411 | 5 Nov 2025 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| 20 Oct 2026 | KAREN SOARESOfficer | 19,275 | $85.6K | 20 Oct 2026 |
| 19 Oct 2026 | JAMIE REYNOSOOfficer | 4,066 | $18.2K | 19 Oct 2026 |
| 15 Oct 2026 | Joseph Clay ThorntonOfficer | 4,487 | $21.0K | 15 Oct 2026 |
| 15 Oct 2026 | Karen M. SoaresOfficer | 14,341 | $67.1K | 15 Oct 2026 |
| 15 Oct 2026 | Jamie ReynosoOfficer | 17,858 | $83.6K | 15 Oct 2026 |
| 15 Oct 2026 | Conrad WaiOfficer | 23,463 | $109.8K | 15 Oct 2026 |
| 15 Oct 2026 | Andrew ToyOfficer | 60,765 | $284.4K | 15 Oct 2026 |
| 7 Oct 2026 | JAMIE REYNOSOOfficer | 2,006 | $9.2K | 7 Oct 2026 |
| 5 Oct 2026 | Jamie ReynosoOfficer | 8,706 | $40.7K | 5 Oct 2026 |
| 1 Oct 2026 | Andrew ToyOfficer | 309,558 | $1.3M | 1 Oct 2026 |
| 24 Sep 2026 | BRADY PRIESTFormer Officer | 141,418 | $631.2K | 24 Sep 2026 |
| 17 Sep 2026 | JAMIE REYNOSOOfficer | 1,921 | $8.8K | 17 Sep 2026 |
| 16 Sep 2026 | Joseph Frank OldakowskiOfficer | 3,170 | $14.7K | 16 Sep 2026 |
| 15 Sep 2026 | Karen SoaresOfficer | 6,416 | $29.9K | 15 Sep 2026 |
| 15 Sep 2026 | Jamie ReynosoOfficer | 8,691 | $40.5K | 15 Sep 2026 |
| 15 Sep 2026 | BRADY PRIESTFormer Officer | 215,291 | $999.6K | 15 Sep 2026 |
| 15 Sep 2026 | WAI CONRADOfficer | 300,000 | $1.4M | 15 Sep 2026 |
| 14 Sep 2026 | JOSEPH OLDAKOWSKIOfficer | 20,000 | $103.1K | 14 Sep 2026 |
| 31 Aug 2026 | BRADY PRIESTOfficer | 73,516 | $305.1K | 31 Aug 2026 |
| 17 Aug 2026 | Joseph Clay ThorntonOfficer | 16,942 | $72.3K | 17 Aug 2026 |
| 14 Aug 2026 | BRADY PRIESTOfficer | 474,801 | $2.2M | 14 Aug 2026 |
| 10 Aug 2026 | Andrew ToyOfficer | 85,704 | $391.7K | 10 Aug 2026 |
| 7 Aug 2026 | BRADY PRIESTOfficer | 441,601 | $2.1M | 7 Aug 2026 |
| 20 Jul 2026 | KAREN SOARESOfficer | 51,700 | $238.9K | 20 Jul 2026 |
| 17 Jul 2026 | JAMIE REYNOSOOfficer | 4,839 | $21.3K | 17 Jul 2026 |
| 15 Jul 2026 | Joseph Clay ThorntonOfficer | 4,486 | $21.0K | 15 Jul 2026 |
| 15 Jul 2026 | Karen SoaresOfficer | 10,192 | $47.7K | 15 Jul 2026 |
| 15 Jul 2026 | Jamie ReynosoOfficer | 12,712 | $59.5K | 15 Jul 2026 |
| 15 Jul 2026 | Conrad WaiOfficer | 23,463 | $109.8K | 15 Jul 2026 |
| 15 Jul 2026 | Andrew ToyOfficer | 60,765 | $284.4K | 15 Jul 2026 |
| 8 Jul 2026 | JAMIE REYNOSOOfficer | 2,384 | $11.9K | 8 Jul 2026 |
| 6 Jul 2026 | Jamie ReynosoOfficer | 6,229 | $32.8K | 6 Jul 2026 |
| 1 Jul 2026 | Andrew ToyOfficer | 309,558 | $1.7M | 1 Jul 2026 |
| 17 Jun 2026 | JAMIE REYNOSOOfficer | 2,360 | $11.7K | 17 Jun 2026 |
| 16 Jun 2026 | Joseph Frank OldakowskiOfficer | 14,155 | $69.9K | 16 Jun 2026 |
| 15 Jun 2026 | Karen SoaresOfficer | 5,342 | $25.7K | 15 Jun 2026 |
| 15 Jun 2026 | Jamie ReynosoOfficer | 7,556 | $36.3K | 15 Jun 2026 |
| 11 Jun 2026 | JAMIE REYNOSOOfficer | 7,289 | $35.6K | 11 Jun 2026 |
| 28 May 2026 | Wai ConradOfficer | 220,426 | $880.6K | 28 May 2026 |
| 18 May 2026 | CARLADENISE A EDWARDSDirector | 67,160 | $229.1K | 18 May 2026 |
| 14 May 2026 | Kuipers Peter J.former CFO | 886,341 | $3.1M | 14 May 2026 |
| 13 May 2026 | BRADY PRIESTOfficer | 98,039 | $345.1K | 13 May 2026 |
| 18 Mar 2026 | JAMIE REYNOSOOfficer | 5,833 | $11.3K | 18 Mar 2026 |
| 4 Mar 2026 | BRADY PRIESTOfficer | 175,000 | $378.9K | 4 Mar 2026 |
| 20 Jan 2026 | JAMIE REYNOSOOfficer | 4,597 | $11.7K | 20 Jan 2026 |
| 7 Jan 2026 | JAMIE REYNOSOOfficer | 2,102 | $5.4K | 7 Jan 2026 |
| 18 Dec 2025 | JAMIE REYNOSOOfficer | 4,913 | $12.8K | 18 Dec 2025 |
| 4 Nov 2025 | JAMIE REYNOSOOfficer | 30,385 | $111.8K | 4 Nov 2025 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| 26 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
Trades by members of the House
From each member's periodic transaction report: the amount is the band the report gives.
No House trades in this company.
Short interest
Shares sold short and not yet bought back, on every FINRA settlement date.
Shares short, each settlement
| 15 Oct 2026 | 25.9M | +13.31% | 5.34 |
| 30 Sep 2026 | 22.9M | -2.33% | 6.3 |
| 15 Sep 2026 | 23.4M | -0.98% | 5.18 |
| 31 Aug 2026 | 23.7M | -9.43% | 6.87 |
| 14 Aug 2026 | 26.1M | -7.42% | 4.98 |
| 31 Jul 2026 | 28.2M | -1.78% | 7.18 |
| 15 Jul 2026 | 28.7M | +29.59% | 4.89 |
| 30 Jun 2026 | 22.2M | -10.73% | 2.8 |
| 15 Jun 2026 | 24.9M | -13.1% | 2.49 |
| 29 May 2026 | 28.6M | -23.52% | 3.47 |
1–10 of 139
Funds that hold it
Every fund's holding from its latest Form 13F, largest first, with what it added or trimmed in the quarter.
Funds holding
252
quarter to 30 Jun 2026
Added or new
117
since 31 Mar 2026
Trimmed
56
in the quarter
Largest holder
BlackRock, Inc.
$184.0M
The 60 largest of 252 funds, by value
1–50 of 60
Dividends and buybacks
Dividend per share, the cash paid and the shares bought back, each fiscal year.
This company has paid no dividend in the years held.
Peers
Companies in the same industry, largest first, on the same measures.
| Company | Market value | Revenue, 12 months | Revenue growth | Operating margin | Net margin | ROE | P/E | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|
| Clover Health Investments, Corp.this company | $2.5B | $2.5B | 54.0% | -0.7% | -0.7% | -4.9% | – | – |
| UnitedHealth Group Inc. | $371.7B | $450.1B | 6.5% | 4.8% | 3.1% | 13.5% | 26.4× | 16.0× |
| Elevance Health, Inc. | $91.2B | $201.8B | 3.6% | 2.7% | 2.5% | 11.5% | 18.0× | 16.1× |
| Cigna Group | $78.8B | $282.4B | 7.8% | 3.5% | 2.3% | 15.1% | 12.3× | 8.2× |
| Humana Inc. | $50.1B | $145.7B | 18.3% | 1.9% | 0.9% | 6.7% | 39.5× | 17.1× |
| Centene Corp. | $34.0B | $203.9B | 9.7% | 0.5% | 0.7% | 6.6% | 23.5× | 12.9× |
| Molina Healthcare, Inc. | $10.3B | $44.1B | -0.9% | 0.4% | -0.1% | -1.2% | – | 28.9× |
| Oscar Health, Inc. | $10.3B | $15.3B | 42.8% | 4.1% | 3.6% | 26.8% | 22.0× | 10.1× |
| Alignment Healthcare, Inc. | $1.7B | $4.9B | 35.9% | 0.9% | 0.6% | 10.4% | 61.6× | 16.9× |
| Trupanion, Inc. | $1.3B | $1.5B | 11.8% | 1.6% | 1.5% | 5.7% | 57.0× | 32.4× |
What the company does
The description for this company is being written.
Free for your personal research, with credit and a link. For API access, bulk files or commercial use, tell us what you need. The data licence